<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p180" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_180{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_180{left:306px;bottom:30px;}
#t3_180{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_180{left:346px;bottom:30px;}
#t5_180{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_180{left:517px;bottom:30px;}
#t7_180{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_180{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_180{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_180{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_180{left:35px;bottom:777px;letter-spacing:0.13px;word-spacing:0.05px;}
#tc_180{left:35px;bottom:754px;letter-spacing:0.12px;word-spacing:-0.55px;}
#td_180{left:35px;bottom:713px;letter-spacing:-0.08px;word-spacing:0.27px;}
#te_180{left:478px;bottom:721px;letter-spacing:-0.01px;}
#tf_180{left:501px;bottom:713px;letter-spacing:0.05px;}
#tg_180{left:35px;bottom:690px;letter-spacing:0.06px;word-spacing:-0.98px;}
#th_180{left:35px;bottom:667px;word-spacing:-1.01px;}
#ti_180{left:35px;bottom:645px;letter-spacing:0.09px;word-spacing:-1px;}
#tj_180{left:35px;bottom:622px;letter-spacing:0.16px;word-spacing:0.03px;}
#tk_180{left:35px;bottom:599px;letter-spacing:0.16px;word-spacing:0.02px;}
#tl_180{left:35px;bottom:575px;letter-spacing:0.03px;word-spacing:-1.07px;}
#tm_180{left:35px;bottom:552px;letter-spacing:0.16px;word-spacing:0.06px;}
#tn_180{left:35px;bottom:529px;letter-spacing:0.21px;word-spacing:-0.03px;}
#to_180{left:35px;bottom:506px;letter-spacing:0.04px;word-spacing:0.14px;}
#tp_180{left:35px;bottom:482px;letter-spacing:0.07px;word-spacing:0.12px;}
#tq_180{left:35px;bottom:459px;letter-spacing:0.17px;word-spacing:0.02px;}
#tr_180{left:35px;bottom:436px;letter-spacing:0.07px;word-spacing:-0.98px;}
#ts_180{left:35px;bottom:413px;letter-spacing:0.07px;word-spacing:-1.09px;}
#tt_180{left:35px;bottom:390px;letter-spacing:-0.02px;word-spacing:0.2px;}
#tu_180{left:35px;bottom:366px;letter-spacing:0.1px;word-spacing:0.08px;}
#tv_180{left:35px;bottom:343px;letter-spacing:0.1px;word-spacing:-0.7px;}
#tw_180{left:35px;bottom:320px;letter-spacing:0.01px;word-spacing:0.18px;}
#tx_180{left:35px;bottom:297px;letter-spacing:-0.18px;}
#ty_180{left:35px;bottom:256px;letter-spacing:0.19px;}
#tz_180{left:35px;bottom:233px;letter-spacing:0.16px;word-spacing:0.02px;}
#t10_180{left:35px;bottom:210px;letter-spacing:0.06px;word-spacing:0.12px;}
#t11_180{left:35px;bottom:187px;letter-spacing:0.14px;word-spacing:0.05px;}
#t12_180{left:35px;bottom:163px;letter-spacing:0.16px;word-spacing:0.03px;}
#t13_180{left:35px;bottom:140px;letter-spacing:0.11px;word-spacing:0.08px;}
#t14_180{left:431px;bottom:148px;letter-spacing:0.1px;}
#t15_180{left:477px;bottom:140px;letter-spacing:0.29px;word-spacing:-0.1px;}
#t16_180{left:35px;bottom:117px;letter-spacing:0.09px;word-spacing:0.1px;}
#t17_180{left:35px;bottom:94px;letter-spacing:-0.03px;word-spacing:-0.47px;}
#t18_180{left:35px;bottom:71px;letter-spacing:0.05px;word-spacing:-0.32px;}
#t19_180{left:618px;bottom:777px;letter-spacing:0.08px;}
#t1a_180{left:732px;bottom:785px;}
#t1b_180{left:777px;bottom:777px;letter-spacing:0.16px;word-spacing:0.03px;}
#t1c_180{left:618px;bottom:754px;letter-spacing:0.01px;word-spacing:0.17px;}
#t1d_180{left:618px;bottom:731px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1e_180{left:618px;bottom:707px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1f_180{left:618px;bottom:684px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1g_180{left:862px;bottom:692px;letter-spacing:-0.01px;}
#t1h_180{left:618px;bottom:645px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1i_180{left:618px;bottom:622px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1j_180{left:618px;bottom:599px;letter-spacing:0.01px;word-spacing:0.18px;}
#t1k_180{left:847px;bottom:606px;letter-spacing:0.06px;}
#t1l_180{left:914px;bottom:599px;letter-spacing:0.01px;word-spacing:0.19px;}
#t1m_180{left:618px;bottom:575px;letter-spacing:-0.03px;word-spacing:0.21px;}
#t1n_180{left:618px;bottom:552px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1o_180{left:618px;bottom:529px;letter-spacing:0.06px;word-spacing:-0.23px;}
#t1p_180{left:618px;bottom:506px;letter-spacing:0.08px;word-spacing:-1.1px;}
#t1q_180{left:922px;bottom:513px;letter-spacing:-0.01px;}
#t1r_180{left:945px;bottom:506px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1s_180{left:618px;bottom:482px;letter-spacing:0.12px;word-spacing:0.09px;}
#t1t_180{left:618px;bottom:459px;letter-spacing:0.09px;word-spacing:0.09px;}
#t1u_180{left:618px;bottom:436px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1v_180{left:618px;bottom:413px;letter-spacing:0.08px;word-spacing:0.11px;}
#t1w_180{left:618px;bottom:390px;letter-spacing:0.06px;word-spacing:0.13px;}
#t1x_180{left:618px;bottom:366px;letter-spacing:0.19px;word-spacing:-0.25px;}
#t1y_180{left:618px;bottom:343px;letter-spacing:0.11px;word-spacing:-0.66px;}
#t1z_180{left:618px;bottom:320px;letter-spacing:0.08px;word-spacing:0.11px;}
#t20_180{left:790px;bottom:327px;letter-spacing:-0.01px;}
#t21_180{left:813px;bottom:320px;word-spacing:0.18px;}
#t22_180{left:618px;bottom:297px;letter-spacing:0.12px;word-spacing:0.07px;}
#t23_180{left:618px;bottom:273px;letter-spacing:0.15px;word-spacing:0.03px;}
#t24_180{left:618px;bottom:250px;letter-spacing:0.12px;word-spacing:0.07px;}
#t25_180{left:618px;bottom:227px;letter-spacing:0.06px;word-spacing:-1.11px;}
#t26_180{left:618px;bottom:204px;letter-spacing:0.08px;word-spacing:0.11px;}
#t27_180{left:618px;bottom:181px;letter-spacing:0.18px;word-spacing:0.01px;}
#t28_180{left:1107px;bottom:188px;letter-spacing:-0.01px;}
#t29_180{left:1131px;bottom:181px;}
#t2a_180{left:618px;bottom:157px;letter-spacing:0.06px;word-spacing:0.13px;}
#t2b_180{left:618px;bottom:134px;letter-spacing:0.14px;word-spacing:0.05px;}
#t2c_180{left:618px;bottom:111px;letter-spacing:0.1px;word-spacing:0.09px;}
#t2d_180{left:618px;bottom:88px;letter-spacing:0.14px;word-spacing:0.04px;}
#t2e_180{left:618px;bottom:64px;letter-spacing:0.12px;word-spacing:0.06px;}
#t2f_180{left:1078px;bottom:72px;letter-spacing:-0.01px;}
#t2g_180{left:1101px;bottom:64px;letter-spacing:0.45px;}
#t2h_180{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_180{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_180{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_180{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_180{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_180{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_180{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_180{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts180" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg180Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg180" style="-webkit-user-select: none;"><object width="1210" height="935" data="180/180.svg" type="image/svg+xml" id="pdf180" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_180" class="t s0_180">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_180" class="t s1_180">© </span>
<span id="t3_180" class="t s0_180">(NCCN </span>
<span id="t4_180" class="t s1_180">© </span>
<span id="t5_180" class="t s0_180">), All rights reserved. NCCN Guidelines </span>
<span id="t6_180" class="t s1_180">® </span>
<span id="t7_180" class="t s0_180">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_180" class="t s2_180">NCCN Guidelines Version 4.2024 </span>
<span id="t9_180" class="t s2_180">Head and Neck Cancers </span>
<span id="ta_180" class="t s3_180">MS-39 </span>
<span id="tb_180" class="t s4_180">single phase 2 study powered based on a 10% noninferiority margin, </span>
<span id="tc_180" class="t s4_180">many practitioners continue to use chemoradiation for T3 N0 M0 disease. </span>
<span id="td_180" class="t s4_180">An individual patient data meta-analysis by Blanchard et al, </span>
<span id="te_180" class="t s5_180">510 </span>
<span id="tf_180" class="t s4_180">which </span>
<span id="tg_180" class="t s4_180">included 19 trials and 4806 patients with non-metastatic NPC, showed that </span>
<span id="th_180" class="t s4_180">both adjuvant chemotherapy following chemoradiation and chemoradiation </span>
<span id="ti_180" class="t s4_180">without adjuvant chemotherapy were associated with better OS (HR, 0.65; </span>
<span id="tj_180" class="t s4_180">95% CI, 0.56–0.76 and HR, 0.80; 95% CI, 0.70–0.93, respectively) and </span>
<span id="tk_180" class="t s4_180">PFS (HR, 0.62; 95% CI, 0.53–0.72 and HR, 0.81; 95% CI, 0.71–0.92, </span>
<span id="tl_180" class="t s4_180">respectively) than radiation without concurrent systemic therapy. However, </span>
<span id="tm_180" class="t s4_180">differences between the included studies assessing chemoradiation with </span>
<span id="tn_180" class="t s4_180">and without adjuvant chemotherapy (eg, different length of follow-up, </span>
<span id="to_180" class="t s4_180">fewer patients with stage II disease in trials assessing adjuvant </span>
<span id="tp_180" class="t s4_180">chemotherapy) limited the ability to make a firm conclusion regarding the </span>
<span id="tq_180" class="t s4_180">efficacy of one treatment modality over the other. The NRG-HN001 trial </span>
<span id="tr_180" class="t s4_180">(NCT02135042), a phase II/III study, aimed to investigate whether delivery </span>
<span id="ts_180" class="t s4_180">of adjuvant chemotherapy should be eliminated or intensified based on the </span>
<span id="tt_180" class="t s4_180">status of EBV DNA plasma levels after chemoradiation. This trial was </span>
<span id="tu_180" class="t s4_180">closed slightly prematurely due to slowing accrual; as of March 2024, </span>
<span id="tv_180" class="t s4_180">insufficient events had occurred to evaluate the value of the post radiation </span>
<span id="tw_180" class="t s4_180">serum EBV DNA level as a biomarker for adjuvant treatment decision- </span>
<span id="tx_180" class="t s4_180">making. </span>
<span id="ty_180" class="t s4_180">There is substantial evidence supporting the use of induction </span>
<span id="tz_180" class="t s4_180">chemotherapy followed by concurrent systemic therapy/RT for treatment </span>
<span id="t10_180" class="t s4_180">of locoregionally advanced nasopharyngeal cancer. Two randomized </span>
<span id="t11_180" class="t s4_180">phase III trials from China published in 2019 show a survival benefit for </span>
<span id="t12_180" class="t s4_180">induction chemotherapy followed by concurrent systemic therapy/RT, </span>
<span id="t13_180" class="t s4_180">compared to concurrent systemic therapy/RT alone. </span>
<span id="t14_180" class="t s5_180">511,512 </span>
<span id="t15_180" class="t s4_180">Results from </span>
<span id="t16_180" class="t s4_180">multiple systematic reviews suggest that induction chemotherapy prior to </span>
<span id="t17_180" class="t s4_180">systemic therapy/RT in patients with locally advanced NPC may potentially </span>
<span id="t18_180" class="t s4_180">impact tumor control, compared to systemic therapy/RT without additional </span>
<span id="t19_180" class="t s4_180">chemotherapy. </span>
<span id="t1a_180" class="t s5_180">513-516 </span>
<span id="t1b_180" class="t s4_180">However, these reviews had inconsistent results </span>
<span id="t1c_180" class="t s4_180">when evaluating the impact on survival. Based on comparisons with </span>
<span id="t1d_180" class="t s4_180">systemic therapy/RT alone, induction chemotherapy appears to perform </span>
<span id="t1e_180" class="t s4_180">better than adjuvant chemotherapy for some outcomes, such as in </span>
<span id="t1f_180" class="t s4_180">reduction of distant metastases. </span>
<span id="t1g_180" class="t s5_180">517 </span>
<span id="t1h_180" class="t s4_180">Currently available evidence generally favors the addition of induction </span>
<span id="t1i_180" class="t s4_180">chemotherapy to concurrent systemic therapy/RT in patients with </span>
<span id="t1j_180" class="t s4_180">locoregionally advanced NPC. </span>
<span id="t1k_180" class="t s5_180">513-516,518 </span>
<span id="t1l_180" class="t s4_180">A 2017 network meta-analysis </span>
<span id="t1m_180" class="t s4_180">based on an individual patient data meta-analysis (including 20 trials and </span>
<span id="t1n_180" class="t s4_180">5144 patients) showed that the addition of adjuvant chemotherapy to </span>
<span id="t1o_180" class="t s4_180">chemoradiation was associated with better PFS (HR, 0.81; 95% CI, 0.66– </span>
<span id="t1p_180" class="t s4_180">0.98), compared to chemoradiation only. </span>
<span id="t1q_180" class="t s5_180">513 </span>
<span id="t1r_180" class="t s4_180">The authors argued that more </span>
<span id="t1s_180" class="t s4_180">chemotherapy, in addition to concurrent chemoradiation, could reduce </span>
<span id="t1t_180" class="t s4_180">recurrence rates. A 2023 update to this meta-analysis which included 28 </span>
<span id="t1u_180" class="t s4_180">trials and 8214 patients continued to show that both induction </span>
<span id="t1v_180" class="t s4_180">chemotherapy and adjuvant chemotherapy were superior to systemic </span>
<span id="t1w_180" class="t s4_180">therapy/RT alone, but induction chemotherapy was associated with </span>
<span id="t1x_180" class="t s4_180">greater benefit for distant progression (HR, 0.66; 95% CI, 0.47–0.93 and </span>
<span id="t1y_180" class="t s4_180">HR, 0.65; 95% CI, 0.53–0.80 for induction chemotherapy with and without </span>
<span id="t1z_180" class="t s4_180">taxanes, respectively). </span>
<span id="t20_180" class="t s5_180">518 </span>
<span id="t21_180" class="t s4_180">A 2017 meta-analysis including 27 trials with </span>
<span id="t22_180" class="t s4_180">7940 patients showed that induction chemotherapy prior to systemic </span>
<span id="t23_180" class="t s4_180">therapy/IMRT ranked best for OS, PFS, and distant failure-free survival, </span>
<span id="t24_180" class="t s4_180">although head-to-head comparisons with other treatment sequences (10 </span>
<span id="t25_180" class="t s4_180">evaluated, including systemic therapy/RT, induction chemotherapy prior to </span>
<span id="t26_180" class="t s4_180">systemic therapy/RT, and systemic therapy/RT followed by adjuvant </span>
<span id="t27_180" class="t s4_180">chemotherapy, all with IMRT or 2D/3D RT) were not performed. </span>
<span id="t28_180" class="t s5_180">519 </span>
<span id="t29_180" class="t s4_180">A </span>
<span id="t2a_180" class="t s4_180">randomized phase III trial from the Hong Kong Nasopharyngeal Cancer </span>
<span id="t2b_180" class="t s4_180">Study Group showed a survival benefit when comparing induction </span>
<span id="t2c_180" class="t s4_180">chemotherapy prior to systemic therapy/RT to systemic therapy/RT </span>
<span id="t2d_180" class="t s4_180">followed by adjuvant chemotherapy (cisplatin/5-FU), regardless of the </span>
<span id="t2e_180" class="t s4_180">induction regimen used (either PF or cisplatin/capecitabine). </span>
<span id="t2f_180" class="t s5_180">520 </span>
<span id="t2g_180" class="t s4_180">The </span>
<span id="t2h_180" class="t s6_180">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
